Inhibitors of the fibroblast growth factor receptor

Abstract

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

1 .- 25 . (canceled) 
     
     
         26 . A compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         27 . A pharmaceutical composition comprising the compound of  claim 26  or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
     
     
         28 . A method of treating a condition mediated by FGFR-4, comprising administering a therapeutically effective amount of the compound of  claim 26 , or a pharmaceutically acceptable salt thereof, to a subject. 
     
     
         29 . A method of treating a condition characterized by overexpression of FGFR-4, comprising administering a therapeutically effective amount of the compound of  claim 26 , or a pharmaceutically acceptable salt thereof, to a subject. 
     
     
         30 . A method of treating a condition characterized by amplified FGF-19, comprising administering a therapeutically effective amount of the compound of  claim 26 , or a pharmaceutically acceptable salt thereof, to a subject. 
     
     
         31 . A method of treating a condition characterized by overexpression of FGF-19, comprising administering a therapeutically effective amount of the compound of  claim 26 , or a pharmaceutically acceptable salt thereof, to a subject. 
     
     
         32 . A method of treating cancer, the method comprising administering to a subject a therapeutically effective amount of the compound of  claim 26 , or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from the group consisting of liver cancer, breast cancer, lung cancer, ovarian cancer, and a sarcoma. 
     
     
         33 . A method of treating hepatocellular carcinoma, the method comprising administering to a subject a therapeutically effective amount of the compound of  claim 26 , or a pharmaceutically acceptable salt thereof. 
     
     
         34 . A method of treating hyperlipidemia, the method comprising administering to a subject a therapeutically effective amount of the compound of  claim 26 , or a pharmaceutically acceptable salt thereof.